Vermont spent millions on suspect drug Zyprexa
March 28, 2008
By Daniel Barlow
MONTPELIER – As the lawsuits against Eli Lilly over its top-selling anti-schizophrenia drug Zyprexa began piling up in 2006, Vermont's state-run insurance program spent nearly $4 million on the drug, according to documents.
That amount may seem like a drop in the bucket when compared to Zyprexa's 2007 sales of $4.8 billion in the United States, but the payments through Vermont's Medicaid program came at a time when 10 states and upwards of 30,000 people were suing the company over the drug.
Launched in 1996, Zyprexa has become the top-selling medication for drug-maker Eli Lilly. But those sales are dropping as lawsuits and leaked corporate documents reveal a decade-long effort to downplay the side effects, including weight gain and an increased chance of diabetes, in the company's promotion of the drug.